Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M000340200 on April 14, 2000

J. Biol. Chem., Vol. 275, Issue 24, 18172-18179, June 16, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/24/18172    most recent
M000340200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bellmann, K.
Right arrow Articles by Landry, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bellmann, K.
Right arrow Articles by Landry, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

p38-dependent Enhancement of Cytokine-induced Nitric-oxide Synthase Gene Expression by Heat Shock Protein 70*

Kerstin BellmannDagger §, Volker Burkart, Joerg Bruckhoff, Hubert Kolb, and Jacques LandryDagger

From the Dagger  Centre de Recherche en Cancérologie de l'Université Laval, L'Hôtel-Dieu de Québec, 9, rue McMahon, Québec (Qc) G1R 2J6, Canada and the  German Diabetes Research Institute, Immunobiology Section, Auf'm Hennekamp 65, D-40225 Düsseldorf, Germany

Received for publication, January 18, 2000, and in revised form, April 2, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Heat shock protein (hsp) 70 protects cells against stress by means of its ability to chaperone denatured proteins and to modulate stress-activated signaling pathways. Because inflammatory processes are often accompanied by hsp expression and because stress and cytokines share several signaling pathways, we investigated the possibility that hsp70 might modulate the cellular response to cytokines. We found that stable cell clones overexpressing hsp70, or cells shortly after transfection with hsp70, produced 2 times more nitric oxide and inducible nitric-oxide synthase (iNOS) protein and mRNA in response to cytokines than control cells expressing undetectable amounts of hsp70. Since mitogen-activated protein kinases participate in the activation of iNOS by cytokines, we investigated whether hsp70 affected the activation of these signaling pathways. hsp70 overexpression led to a specific enhancement of the activation of the p38 pathway by cytokines, producing little or no effect on the activation of extracellular signal-regulated kinase or Jun N-terminal kinase. Blocking p38 activity with SB203580 totally abolished the enhancing effect of hsp70 on cytokine-induced endogenous iNOS mRNA accumulation or transcription of an iNOS promoter-driven luciferase gene, while having little effect on the cytokine response observed in control cells. We conclude that the p38 pathway acts as an enhancing factor in the activation of iNOS by cytokines and that hsp70 can modulate the cellular response to cytokines by acting on signaling elements upstream of p38.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Overexpression of hsp701 as a result of transcriptional activation after heat shock or genetic manipulation renders cells resistant to a variety of toxic agents including heat shock, TNFalpha , UV irradiation, oxygen radicals, and NO (1-4). During protein damaging treatments such as heat shock, the capacity of hsp70 to bind denatured proteins provides protection by preventing protein aggregation, accelerating refolding, and mediating degradation of damaged proteins (5-7). Hsp70 can also provide cellular protection by interfering with apoptosis induction (8, 9). One proposed mechanism involves the inhibition of the activation of the MAP kinases JNK and p38, two stress-activated protein kinases which contribute in some conditions to induction of apoptosis (10, 11).

The stress-activated protein kinases JNK and p38, together with ERK, belong to the family of MAP kinases which are involved in the cellular response to most external stimuli. Whereas ERK is preferentially activated by growth factors, JNK and p38 are most strongly activated by chemical and physical stresses and by inflammatory cytokines (12). The role of p38 in the cellular response to cytokines is particularly well documented. p38 was discovered as a major LPS-activated protein kinase in macrophages and as the target for a group of anti-inflammatory drugs which inhibit IL-1beta and TNFalpha biosynthesis in monocytes (13, 14). p38 is activated by different pro-inflammatory agents and modulates the expression of several specific cytokines. Pharmacological or molecular inhibition of p38 results in reduced production of proinflammatory cytokines by fibroblasts and macrophages and impairs IFN-gamma production in T helper 1 cells (13, 15-18). Both transcriptional and post-transcriptional regulatory mechanisms have been described. One key element of the action of p38 is its downstream target MAPKAP kinase-2, which regulates both the stability and the translation of cytokine mRNAs containing AU-rich sequences in their 3'-untranslated region (19, 20). p38 also phosphorylates and/or modulates the activity of a number of transcriptional factors involved in cytokine response such as STAT1, IFN regulatory factor-1, and NF-kappa B (15, 21-25).

The finding that hsp70 can modulate the activation of stress-activated signaling pathways raises the intriguing possibility that it may play a role in inflammatory and autoimmune diseases which are often associated with disregulated expression of cytokines (10, 11). A number of circumstantial evidence suggests a role of hsp in cytokine signal transduction and in the control of cytokine expression. Heat shock treatments sufficient to induce hsp accumulation reduced TNFalpha and IL-1beta induction in monocytes after stimulation with LPS (26-28). In other studies heat shock either reduced or enhanced cytokine-stimulated NO production (29-32). On the other hand, cytokines can also induce hsp expression. In human monocytes, LPS and TNFalpha lead to the increased expression of hsp70 (33). A similar induction of hsp70 by cytokines has been reported in nonimmune cells such as rat pancreatic islets and cardiac myocytes (34, 35). This adds to more direct evidence indicating that hsp70, as other hsp, is involved in antigen presentation and mediates the induction of T helper 1-type cytokines in immune cells thus increasing cellular immunity (36, 37). Finally, the detection of antibodies against hsp in some autoimmune disorders including type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus suggests that hsp are implicated in the autoimmune disease process (38, 39).

In the present study, we investigated the possible role of hsp70 as a modulator of the cellular response to cytokines using iNOS as a model system for cytokine inducible genes. In two different rodent cell types, we showed that hsp70 increased the expression of iNOS and the production of nitric oxide. Furthermore, we provide evidence that this effect results from an hsp70-mediated enhancement of the activation of p38 by cytokines suggesting a novel role for hsp70 as a p38-dependent modulator of inflammatory responses.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- [gamma -32P]ATP (3000 Ci/mmol) was purchased from NEN Life Sciences Products (Boston, MA). Mouse IL-1beta , H2O2, puromycin, and LPS were from Sigma (Windsor, Ontario, Canada), rat IFN-gamma was from Genzyme (Cambridge, MA), SB203580 was from Calbiochem (San Diego, CA). Recombinant hsp27, ATF2-GST, and c-Jun-GST were purified from Escherichia coli transformed with appropriate plasmids (40-42). Chemicals for electrophoresis were obtained from Bio-Rad and Fisher Scientific (Nepean, Ontario, Canada).

Antibodies-- Anti-HA is a mouse monoclonal antibody that recognizes a peptide sequence from human influenza hemagglutinin protein (Roche Molecular Biochemicals, Mannheim, Germany). The rabbit polyclonal antibody against iNOS was from Dianova (Hamburg, Germany). The rabbit polyclonal antibody anti-hsp70 (number 799) recognizes the inducible form of hsp70 (43); anti-GST-MAPKAP kinase-2, the p45 and p54 isoforms of MAPKAP kinase-2 (44); and anti-ERK, the 14 carboxyl-terminal amino acids of ERK-2 (44). Antibodies against phosphorylated MKK3/6 and MKK4 were obtained from New England Biolabs (Beverly, MA).

Cell Culture-- The rat insulinoma cell line RINm5F (hsp70 transfected clones R70/20 and R70/3, and transfection control clone RK/1 (4)) and the mouse fibrosarcoma cell line WEHI (hsp70 transfected clone Wn113-5 and control clone Wn10x (1)) were cultured at 37 °C in a humidified air atmosphere with 5% CO2 in RPMI 1640 medium (Life Technologies, Burlington, Ontario, Canada) supplemented with 2 g/liter NaHCO3, 2.38 g/liter Hepes (pH 7.3), and 10% heat-inactivated fetal bovine serum (Life Technologies). For heat shock treatment, RINm5F cells were seeded in flat bottom microtiter plates at 2 × 104 cells in 120 µl/well. The cells were exposed to 42.5 °C for 90 min. WEHI cells were heat treated in Parafilm-sealed 6-cm Petri dishes which were immersed for 60 min into a circulating water bath thermoregulated at 43 °C.

Transfection-- The plasmid pZEM-hsp70-tag was used for the expression of human hsp70 (4) (pcDNA3-HA-p38, to express HA-tagged p38 (45) and pMT2-SAPKbeta to express HA-tagged JNK (46)). pcDNA3-ashsp70 contains 500 base pairs of the human hsp70 gene in the antisense orientation (9). piNOS-1002-luc contains the first 1002 base pairs of the rat iNOS promoter coupled to the firefly luciferase gene (47). DNA was introduced into RIN cells by lipofection with Lipofect (Promega, Madison, WI) according to the manufacturer's instructions. Cells were seeded 24 h before transfection at 2 × 105 cells in 24-well plates. The DNA/lipid mixture contained 0.5 µg of the test plasmid and 2.3 µl of the lipofection reagent in 200 µl of cell culture medium. Cells were exposed to the DNA/lipid mixture for 1 h in culture medium without serum, then fresh medium with 10% serum was added. Twenty-four h post-transfection the cells were treated with IL-1beta for 6 h. WEHI cells were transfected with the calcium-phosphate method as described previously (48). Cells were seeded at a density of 0.5 × 105 cells in 6-well plates and transfected with 4 µg of plasmid per well. 50 µM Chloroquine was added for the first 5 h of transfection. The cells were used 24 h after transfection.

Nitrite Determination-- Cells were seeded at a density of 8 × 104 cells (R70/20 and RK/1) or 5 × 104 cells (Wn113-5 and Wn10x) in 96-well tissue culture plates. After stimulation, the supernatants were collected and nitrite levels as an indirect measurement of nitric oxide production were determined by the Griess method as described previously (49).

Luciferase Assay-- After treatment for 6 h the cells were scraped in 150 µl of lysis buffer (25 mM Hepes, pH 7.40, 1 mM EGTA, 1 mM EDTA, 8 mM MgCl2, 10% glycerol, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100). Luciferase activity was determined as described previously (50).

Western Blot-- Cells were washed twice with ice-cold phosphate-buffered saline and scraped off culture dishes. After extraction in lysis buffer, proteins were boiled for 5 min, electrophoresed in 10% SDS-polyacrylamide gels, and blotted onto a nitrocellulose filter (51). After reacting the membranes with the specific antibodies the detection step was performed using an ECL detection kit (Amersham Pharmacia Biotech) or by iodinated secondary antibodies and quantification using the PhosphorImager analysis (Molecular Dynamics, Sunnyvale, CA).

mRNA Isolation and RT-PCR-- Total RNA was isolated after removal of the supernatant and lysis of the cells in Trizol (Life Technologies). Specific mRNA levels were determined and quantified by RT-PCR as described elsewhere (52, 53) using specific primers for beta -actin (CLONTECH Laboratories Inc., Palo Alto, CA) and iNOS (53). RT-PCR products were labeled by hybridization to 32P-labeled probes binding at sites between the primer sequences. iNOS mRNA levels were quantified by measuring the 32P-stimulated luminescence by PhosphorImager analysis. Relative luminescence was calculated by normalization of the measured signals to the strength of the beta -actin signals.

Immunoprecipitation and Kinase Assays-- Cells were seeded at a density of 3 × 105/ml and incubated for at least 16 h at 37 °C. After stimulation the cells were scraped in lysis buffer containing 20 mM MOPS, pH 7.0, 10% glycerol, 80 mM beta -glycerophosphate, 5 mM EGTA, 0.5 mM EDTA, 1 mM Na3VO4, 5 mM Na4P2O7, 50 mM sodium fluoride, 1% Triton X-100, 1 mM benzamidine, 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride. After vortexing, the extracts were centrifuged at 17,000 × g for 10 min at 4 °C and the supernatants were stored at -80 °C. The following steps were performed at 4 °C. The supernatants were diluted four times in buffer A (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1 mM EDTA, 1 mM EGTA, 1 mM MgCl2, 1 mM Na3VO4, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride). Undiluted anti-ERK2, anti-MAPKAP kinase-2, or anti-HA-tag antibodies were added in limiting concentrations. After 1 h, protein A-Sepharose (Amersham Pharmacia Biotech, 50% v/v in buffer A) was added for another 30 min. The samples were centrifuged for 15 s and washed three times with 300 µl of buffer A. Immunoprecipitates were used directly for kinase assays. MAPKAP kinase-2, ERK2, and p38 activities were determined in immune complexes using appropriate substrates. MAPKAP kinase-2 activity was determined using recombinant hsp27 as substrate (44). The assays were done in 20 µl of buffer K (100 µM ATP, 3 µCi of [gamma -32P]ATP, 40 mM p-nitrophenyl phosphate, 20 mM MOPS, pH 7.0, 10% glycerol, 15 mM MgCl2, 0.05% Triton X-100, 1 mM dithiothreitol, 1 µM leupeptin, 0.1 mM phenylmethylsulfonyl fluoride). The kinase activity was assayed for 30 min at 30 °C and stopped by boiling in SDS sample buffer. Immunoprecipitated ERK2 and p38 were assayed analogously using myelin basic protein and GST-ATF-2, respectively, as substrates. Kinase assay buffer K containing 10 mM MgCl2 was used for ERK2. The assay buffer for p38 contained 50 mM Hepes, pH 7.4, 50 mM beta -glycerophosphate, 50 mM MgCl2, 0.2 mM Na3VO4, 4 mM dithiothreitol, ATF2-GST, and [gamma -32P]ATP. In the case of JNK, the cell extract was adsorbed on GST-Jun beads and the kinase tested using the same GST-N-terminal Jun as substrate (42). Briefly, the GST-Jun fusion protein was incubated for 30 min at 4 °C with the extracts. The beads were then pelleted, washed, and incubated for 30 min at 30 °C with 3 µCi of [gamma -32P]ATP in buffer K containing 10 mM MgCl2. The phosphorylated GST-Jun was boiled in SDS sample buffer to stop the reaction. The activity of the various kinases was quantified by measuring the incorporation of radioactivity into the specific substrate by PhosphorImager analysis after electrophoresis.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

hsp70 Enhanced NO Production and iNOS Gene Expression-- To test whether hsp have any influence on the cellular response to cytokines, RIN cells were exposed to heat shock, allowed to recover for 1 or 24 h at 37 °C, and then exposed to IL-1beta . The nitrite content of the supernatant was determined thereafter and used as a parameter for stimulated NO production. Heat shock caused an immediate reduction of the ability of the cells to produce NO in response to IL-1beta , but slightly enhanced this response at 24 h, at a time when the concentration of hsp70 had increased severalfold in the cells (Fig. 1A).


View larger version (15K):
[in this window]
[in a new window]
  		Fig. 1.   Effect of heat shock or hsp70 expression on cytokine-induced NO production. A, RIN cells were either sham (Control) or heat-treated (HS) at 42.5 °C for 90 min. After a recovery period of 1 h (HS+1) or 24 h (HS+24) the cells were treated for 24 h with IL-1beta (10 units/ml). B, parental RIN cells (open circles), empty vector transfected RIN cells (RK/1; open triangles), and two hsp70 overexpressing clones (R70/3, filled triangles; R70/20, filled squares) were treated for 12 and 24 h with IL-1beta . C, the empty vector transfected Wn10x and hsp70 overexpressing Wn113-5 cells were treated for the indicated period of time with a combination of IFN-gamma (100 units/ml) and LPS (100 ng/ml). Shown are the mean + S.D. of nitrite levels measured in the cell supernatants from three separate experiments. When not shown, error bars are smaller than the symbols. Insets, cell extracts were prepared from aliquots before adding the cytokines to determine hsp70 levels by Western. Each lane was loaded with amounts of proteins equivalent to 105 cells.

To determine more directly whether hsp70 could be the molecule responsible for the modulation of NO production, cytokine-induced NO production was evaluated in RIN and WEHI cells and compared with clones of these cell lines that constitutively express hsp70. Twenty-four hours after treatment with IL-1beta , RIN cell clones overexpressing hsp70 (R-70/20 and R-70/3) produced a level of nitrite 2-3 times higher than control-transfected (RK/1) or wild type RIN cells (Fig. 1B). Similarly, treatment with LPS and IFN-gamma resulted in a 3-fold increased nitrite production in the hsp70-overexpressing WEHI cell line Wn113-5 as compared with the empty vector transfected Wn10x cells (Fig. 1C). In both cell lines, the time course analysis revealed not only an increase but also a more rapid induction of NO production. Since NO activity depends on de novo protein synthesis we determined the effect of hsp70 overexpression on iNOS mRNA and protein expression. WEHI cell clones were treated with LPS and IFN-gamma and total RNA was isolated and analyzed by RT-PCR. iNOS mRNA increased more rapidly and to 2-fold higher levels in the hsp70-transfected cells compared with the control cells (Fig. 2A). Western blot analysis of protein extracts of IL-1beta -treated RIN cells and LPS/IFN-gamma -treated WEHI cells showed a similar hsp70-mediated enhancement in the expression of the iNOS protein (Fig. 2B).


View larger version (31K):
[in this window]
[in a new window]
  		Fig. 2.   Effect of hsp70 on cytokine-induced iNOS mRNA and protein expression. A, control Wn10x cells (open circles) and hsp70-expressing Wn113-5 cells (filled squares) were treated with IFN-gamma (100 units/ml) and LPS (100 ng/ml). At various times thereafter, total RNA was isolated and the iNOS and beta -actin mRNA amplified by RT-PCR. The amounts of iNOS mRNA were quantified by PhosphorImaging and values of phosphostimulated luminescence (PSL) were calibrated to the amount of beta -actin mRNA. Shown are means of three experiments + S.D. B, Wn10x and Wn113-5 cells were treated as in A; RIN and R70/20 cells were treated with IL-1beta (10 units/ml). Total protein lysates were prepared 24 h later and analyzed by Western blot to determine iNOS protein expression.

hsp70 Enhanced p38 MAP Kinase Activation-- MAP kinases are in many cell lines important modulators of iNOS gene induction. We analyzed the activity of the MAP kinases p38, JNK, and ERK after stimulation with LPS and IFN-gamma in control versus hsp70 overexpressing WEHI cell clones. Hsp70 caused a major change both in the kinetics and strength of p38 activation measured either by the in vivo activation of its downstream target MAPKAP kinase-2 (Fig. 3) or directly by measuring the activity of immunoprecipitated p38 (data not shown). A maximal difference in activity was observed at 10 min after exposure, at which time MAPKAP kinase-2 activity was induced about 12-fold in hsp70-overexpressing WEHI cells as compared with 2-fold in control cells. A similar hsp70-dependent enhancement of MAPKAP kinase-2 activation was observed in WEHI or RIN cells exposed to IL-1beta (see below and data not shown). LPS/IFN-gamma induced no significant ERK activity in either control or hsp70-expressing WEHI cells. JNK was strongly activated by this treatment, however, in several experiments no or little difference was obtained between control and hsp70-expressing cells.


View larger version (40K):
[in this window]
[in a new window]
  		Fig. 3.   Effect of hsp70 expression on cytokine-induced MAP kinase activity. Control Wn10x cells (open circles) and hsp70-expressing Wn113-5 cells (filled squares) were treated with IFN-gamma (100 units/ml) and LPS (100 ng/ml). At various times thereafter, cell extracts were prepared and processed to determine the activity of MAPKAP kinase-2 (MAPKAP-K2, A), JNK (B), and ERK (C) using the appropriate proteins as substrate. The radiolabeled substrates were then separated by electrophoresis and the kinase activities visualized by autoradiography and quantified by PhosphorImager analysis. The relative induction of kinase activity was calculated by setting the value for untreated controls as 1. Graphs on the left are from average values of two experiments. Representative autoradiograms are shown on the right.

The effect of hsp70 expression on MAP kinase activation was reproduced in a transient transfection assay. Parental WEHI cells were transfected with HA-tagged p38 or HA-tagged JNK constructs together with increasing concentrations of the hsp70 expression vector. Twenty-four hours later the cells were treated with LPS/IFN-gamma for 15 min and the activity of the transfected kinase was determined after immunoprecipitation with a limiting concentration of a HA antibody. A progressive enhancement of p38 activation was obtained with increasing concentrations of hsp70. Furthermore, transfection of a hsp70 antisense construct in hsp70 overexpressing WEHI clones reduced the activation of HA-p38 kinase. At similar concentrations, hsp70 had no effect on the activation of HA-tagged JNK (Fig. 4).


View larger version (29K):
[in this window]
[in a new window]
  		Fig. 4.   Effect of hsp70 concentration on cytokine-induced p38 kinase activity. A-C, Wn10x cells were co-transfected with HA-tagged p38 together with varying concentrations of hsp70 (pZhsp70tag) or control (pZEMneo) plasmids. Twenty-four hours later, cells were treated (+) with IFN-gamma (100 units/ml) and LPS (100 ng/ml) for 15 min or left untreated (-) and HA-tagged p38 was immunoprecipitated to determine p38 activity using ATF2-GST as substrate. Shown are the calculated relative induction of kinase activity (A), the autoradiogram of labeled ATF2 (B), and for each condition the level of hsp70 in cell extracts determined by Western blot analysis (C). D and E, cells were processed as above except that they were co-transfected with HA-tagged JNK. The relative induction of immunoprecipitated HA-JNK was calculated (D) after measuring the level of phosphorylation c-Jun-GST used as substrate (E). F and G, HA-tagged p38 activity in Hsp70-overexpressing Wn113-5 cells which were co-transfected with HA-tagged p38 together with antisense-hsp70 (ashsp70) plasmids at the indicated concentrations and stimulated as above. Both relative induction (F) and ATF2 phosphorylation (G) are shown. Similar results were obtained in three separate experiments.

The hsp70-specific enhancement of p38 kinase activation in response to LPS/IFN-gamma contrasted with previous results showing an inhibition of stress-induced p38 and JNK activation by hsp70 (10, 11). We therefore determined the effect of hsp70 on the activation of p38 by IL-1beta as compared with activation by two toxic stressing treatments, hydrogen peroxide and heat shock. Treatment of hsp70-expressing WEHI cells with IL-1beta led to the same enhancing effect on kinase activity compared with control cells as did the treatment with LPS/IFN-gamma . In contrast, elevated expression of hsp70 led to a reduced hydrogen peroxide and heat shock activation of p38 (Fig. 5). This result suggests that the effect of hsp70 on p38 activation depends on the nature of the activating pathway used by the stimuli.


View larger version (23K):
[in this window]
[in a new window]
  		Fig. 5.   Effect of hsp70 expression on the induction of MAPKAP kinase-2 activity by different treatments. Control Wn10x cells (open circles and hsp70 -) and hsp70-expressing Wn113-5 cells (filled squares and hsp70 +) were treated with 100 units/ml IL-1beta (A and B), 1 mM H2O2 (C and D), or heat shock at 43 °C (E and F). MAPKAP kinase-2 was immunoprecipitated at the indicated times after initiating the treatments and its activity measured using hsp27 as substrate. The relative induction of MAPKAP kinase-2 (A, C, and E) was calculated from the autoradiograms shown in B, D, and F, setting the value of untreated controls as 1. Shown is one of three representative experiments.

Three MAP kinase kinases, MKK4, MKK3, and MKK6, can regulate the activation of p38 (41, 54-56). We therefore looked at the effect of hsp70 on the activation (phosphorylation) of these kinases by LPS/IFN-gamma and hydrogen peroxide (Fig. 6). A major difference was found in the induction of phosphorylation of MKK4 and MKK3/6 by the two stimuli. Hydrogen peroxide treatment led to the phosphorylation of both MKK3/6 and MKK4, although the former was induced more strongly. In contrast, LPS/IFN-gamma treatment induced a strong phosphorylation of MKK4 but no significant increase in the phosphorylation of MKK3/6. As found at the level of p38, hsp70 caused an enhancement in the cytokine-induced phosphorylation, but a reduction in the stress-induced phosphorylation of the MAP kinase kinases, hence suggesting that hsp70 acts further upstream in the specific signaling pathways used by these stimuli.


View larger version (61K):
[in this window]
[in a new window]
  		Fig. 6.   Effect of hsp70 expression on the induction of p38-activating kinases. Control Wn10x (Control) and hsp70-expressing Wn113-5 cells (hsp70) were treated with LPS (100 ng/ml) and IFN-gamma (100 units/ml) or with H2O2 (1 mM) for the times indicated. Cell extracts were prepared and analyzed by Western blot with antibodies directed against phosphorylated MKK3/6 and MKK4. The relative phosphorylation level (indicated under each gel track) was analyzed by densitometry and calculated by setting the value for untreated cells as 1. Shown is one of two experiments which gave essentially the same results.

The Enhancing Effect of hsp70 on iNOS Expression Is p38 Dependent-- The transcription of the iNOS gene is regulated by several transcriptional factors some of which have been shown to be regulated by p38. To verify whether the effect of hsp70 on iNOS expression was due to enhanced transcription, RIN cells were transfected with piNOS-1002LUC, a reporter gene containing the first 1002-base pair upstream sequence of the rat iNOS gene fused to luciferase. As reported previously, this construct contained all necessary information for proper activation by cytokines (47). Upon expression of the reporter gene in RIN cells, a 10-fold increase in luciferase activity was obtained after stimulation with IL-1beta . The same cells also transfected with hsp70 showed a 30-fold increase in luciferase activity, hence, a 3-fold increase in activation relative to control cells (Fig. 7A). No effect of hsp70 expression was observed on the constitutive expression of beta -galactosidase driven by the cytomegalovirus promoter (data not shown).


View larger version (15K):
[in this window]
[in a new window]
  		Fig. 7.   p38 is responsible for the enhancing effect of hsp70 on iNOS gene expression. A, control RIN and hsp70-expressing R70/20 cells were transfected with the rat iNOS promoter construct (piNOS-1002-LUC). Twenty-four hours after transfection the cells were left untreated (control), exposed to the p38 inhibitor SB203580 for 6.5 h (5 µM; SB), exposed to 10 units/ml IL-1beta (IL) for 6 h, or treated with SB203580 for 30 min prior to a 6-h exposure to IL-1beta (SB+IL). Transcriptional activity was determined by measuring luciferase activity in cell extracts. B, control Wn10x cells (open symbols) and hsp70-expressing Wn113-5 cells (filled symbols) were treated with IFN-gamma (100 units/ml) and LPS (100 ng/ml) (circles) or treated with 5 µM SB203580 for 30 min prior to LPS/IFN-gamma exposure (squares). Total RNA was isolated after different time periods and the amount of iNOS mRNA was determined by RT-PCR analysis as described in the legend to Fig. 2. Shown are the mean values + S.D. from three separate experiments. When not shown, error bars are smaller than the symbols.

This result clearly showed that the effect of hsp70 was at the level of the iNOS gene promoter. To verify whether p38 was responsible for the enhancing effect of hsp70 on the transcriptional activation of iNOS, the cells were exposed to IL-1beta in the presence of the p38 inhibitor SB203580. The inhibition of p38 by SB203580 only slightly reduced the luciferase activity in control cells but completely abolished the enhancing effect of hsp70 on iNOS-promoter driven luciferase activity (Fig. 7A). A similar inhibitory effect of SB203580 was obtained on the expression of endogenous iNOS mRNA in control and hsp70-expressing WEHI cells. SB203580 had little if any effect on the iNOS mRNA content of control WEHI cells after stimulation with LPS/IFN-gamma (Fig. 7B), but completely abolished the hsp70 enhancing effect on iNOS expression. These results indicated that p38 can up-regulate cytokine-induced iNOS gene transcription and that an increased activation is responsible for the observed enhancing effect of hsp70.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The work presented in this study stemmed from the observation that heat shock, while causing an initial inhibition of cytokine-induced NO production, resulted at 24 h post-treatment in an enhanced response to cytokines. An inhibition of the cytokine response early after heat shock has been observed previously in different cell types such as rat lung, liver, smooth muscle cells, or glial cells (29-31), and likely results at least in part from initial heat-induced damage. Protein denaturation during heat shock is the trigger for hsp gene transcription. Accumulation of chaperone hsp which bind denatured proteins and assist refolding, facilitates cell recovery. Eventually, accumulation of hsp is also responsible for turning off hsp transcription (57). In the present study, we presented strong evidence that elevated expression of hsp70 after heat shock can modify the cellular response to cytokines. RIN and WEHI cells overexpressing hsp70 produced 2 to 3 times more NO than control cells after treatment with IL-1beta or a combination of LPS and IFN-gamma , respectively. The enhanced NO production did not result from a mere stabilization of iNOS activity through hsp70 chaperone function. Hsp70-mediated enhancement of NO production was accompanied by an increased transcriptional activity of the iNOS gene and an increased accumulation of iNOS mRNA and protein. Furthermore, the effect appears specific to hsp70, since overexpression of another hsp, hsp27, produced no enhancement of NO production (data not shown).

Besides the well documented hsp70 chaperone activity (5-7) which likely contributes to its protective functions during a number of toxic conditions and mediators such as heat shock, TNFalpha (1), reactive radicals (4, 58), or UV light (3), hsp70 also mediates in normal physiological conditions numerous cellular activities including protein synthesis, folding, transport, and degradation (6, 59-61). Here we found that hsp70 expression enhanced LPS/IFN-gamma or IL-1beta -induced p38 MAP kinase activation in WEHI cells. A similar effect was also observed in RIN cells exposed to IL-1beta (data not shown). The effect of hsp70 on p38 activation was concentration dependent. It increased proportionally with the concentration of hsp70 in transiently transfected cells. Furthermore, in cells constitutively expressing hsp70, the enhanced p38 activation could be abrogated by expression of a hsp70 antisense construct. The effect was also specific to p38. Hsp70 overexpression had no effect on cytokine-induced JNK or ERK activation. Finally the effect was specific to cytokines. In the same cells, hsp70 antagonized hydrogen peroxide or heat shock-induced p38 activation.

The mechanisms responsible for the opposite effect of hsp70 on stress activation versus receptor-mediated activation of the p38 signaling pathway is unclear. In the case of stress activation, it is conceivable that the hsp70 inhibitory effects result from an inhibition of the initial damaging event that is responsible for triggering p38 activation. For example, hsp70 was shown to block apoptosis and p38 can be activated downstream of some apoptotic events (9, 62). The findings that hsp70 also reduced activation of the p38-activating kinases MKK3/6 and MKK4 support the view that hsp70 does not act directly on p38 but instead at a level more proximal to the initial triggering event. Thus the action of hsp70 on p38 activation is different from its action on JNK. The inhibition of JNK activation by hsp70 was reported to result from a protection mediated by hsp70 at the level of a JNK phosphatase that is sensitive to protein damaging agents (63). In that study, the mechanism for the inhibition of p38 activation was not identified but was shown to be different. In contrast, in the case of receptor-mediated activation of p38, a chaperone activity of hsp70 at the level of signaling elements that contribute positively to p38 activation may prevail. There are a few reports indicating an association of hsp70 with the proximal elements of signaling pathways other than p38. For example, hsp70 together with hsp90 associate with the inactive glucocorticoid receptor, keeping it in a competent state for activation (64). Hsp70 is also associated with the scaffold complex formed of the kinase suppressor of Ras (KSR), the ERK MAP kinase kinases MEK1 and MEK2 and other proteins (65). Hsp70 was found to bind and increase the stability of the MAP kinase kinase kinase MOS (66). Similarly, elevated expression of the chaperone hsp70 may stabilize or promote the formation of signaling complexes linking cytokine receptors to the p38 activation cascade, resulting in an enhanced activation. Our results showing that hsp70 enhances the activation of p38-activating kinases support such an action of hsp70 early in the signaling pathway.

The study also indicated that the increased activation of p38 was responsible for the hsp70-mediated enhancement of cytokine-induced iNOS expression. The additional iNOS mRNA which accumulated in a hsp70-dependent manner was abolished in the presence of the p38 inhibitor SB203580. Interestingly, p38 activity was not found to play a major role in the basal expression of iNOS in control cells but was responsible for the enhancing effect observed in hsp70-transfected cells. Similar results were obtained in the RIN cell model stimulated by IL-1beta . In these cells overexpression of hsp70 enhanced cytokine-induced transcription of a luciferase reporter gene containing the cytokine-regulated elements of the rat iNOS gene. The enhancement was totally abolished in the presence of the p38 inhibitor, suggesting that the hsp70-mediated effect occurred at the level of transcription and was in major part regulated by p38.

The role of the MAP kinases and in particular p38 in modulating iNOS expression has been investigated in several studies. Varying results have been obtained which likely resulted from the different nature of the cell lines and agonists used, but also from the complexity of the regulatory mechanisms of iNOS regulation and the multitude of targets of p38 which can influence iNOS expression. In macrophages activated by LPS/IFN-gamma , as we found here in control WEHI cells, inhibition p38 activity had little effect on iNOS expression (67, 68). In most cases, however, as we found here in the hsp70 overexpressing cells, inhibition of p38 led to a partial inhibition of the response (23, 69-72). The murine iNOS promoter contains several regulatory elements, of which at least three bind transcriptional factors known to be regulated by the p38 pathway and to be essential for full expression of iNOS. The iNOS promoter contains two NF-kappa B binding motifs. Upon activation, NF-kB translocates to the nucleus and binds to DNA. p38 has little effect on the binding activity but contributes to NF-kB mediated transactivation (15, 24, 25). The most distal region of the iNOS promoter contains 2 regions directly and indirectly regulated by STAT1: an IFN-stimulated response element which binds IFN regulatory factor-1, a factor which is newly synthesized in cells after stimulation with LPS/IFN-gamma (22) and requires STAT1 for its own transcriptional activation, and a IFN-gamma -activated site which binds STAT1 dimers directly (73). Targeted disruption of the STAT1 gene abolishes completely the response to IFN-gamma (74). Recently it has been shown that p38 plays a key role in the phosphorylation of STAT1 at serine 727 and the activation of its transcriptional activity (21, 75). Thus, p38 activity might enhance iNOS transcription directly through STAT1 acting at the IFN-gamma -activated site but also indirectly at the IFN-stimulated response element since blocking p38 activity impairs STAT1 dependent accumulation of IFN regulatory factor-1 after IFN-gamma stimulation (22). In many of these studies, inhibition of p38 activity led to partial inhibition whereas constitutive activation of p38 led to a major enhancement of the response. Thus any factor which like hsp70 can enhance p38 activation would be expected to increase importantly the expression of iNOS. Intriguingly, an insulin-dependent enhancement of iNOS gene expression coupled with an enhancement of p38 activation was also observed in glomerular mesengial cells stimulated with IL-1beta (76).

NO is an important mediator in inflammation and autoimmune diseases (49, 77), acting at high concentrations as a cytotoxic agent and at lower concentrations as an immunoregulatory molecule suppressing T-helper 1-type cytokines such as IFN-gamma and increasing T-helper 2-associated molecules such as IL-4 (78). iNOS is only one of several immunoregulatory genes that are modulated by p38 activity. Pharmacological or molecular inhibition of p38 have revealed important roles of p38 both in the inflammatory response of macrophages and fibroblasts and in the response of T-helper-1 effector cells (13, 15-18, 20). Hsp70 expression is increased in most cell types after stress, during inflammatory or autoimmune processes, and in some cells at specific stages of differentiation (57). The finding that hsp70 can modulate the activation of p38 in response to cytokines and thereby influence the activation of cytokine-regulated genes may reveal important consequences of stress in inflammatory and immune processes.

    ACKNOWLEDGEMENTS

We thank R. M. Tanguay, J. Grose, J. Moscat, M. Jäättelä, J. Woodgett, and D. L. Eizirik for providing several of the antibodies and reagents used in this study.

    FOOTNOTES

* This work was supported by the Medical Research Council of Canada and the Deutsche Forschungsgemeinschaft.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed. Tel.: 418-525-4444 (ext. 5281); Fax: 418-691-5439; E-mail: kerstin.bellmann@crhdq.ulaval.ca.

Published, JBC Papers in Press, April 14, 2000, DOI 10.1074/jbc.M000340200

    ABBREVIATIONS

The abbreviations used are: hsp, heat shock protein(s); ERK, extracellular signal-regulated kinase; IFN, interferon; IL, interleukin; iNOS, inducible nitric-oxide synthase; JNK, Jun N-terminal kinase; LPS, bacterial endotoxic lipopolysaccharide; MAP, mitogen-activated protein; MAPKAP, MAP kinase-activated protein; MKK, MAP kinase kinase; NO, nitric oxide; RT-PCR, reverse transcriptase-polymerase chain reaction, STAT, signal transducer and activator of transcription; TNF, tumor necrosis factor; HA, hemagglutinin; GST, glutathione S-transferase; MOPS, 4-morpholinepropanesulfonic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Jäättelä, M., Wissing, D., Bauer, P. A., and Li, G. C. (1992) EMBO J. 11, 3507-3512
2. Li, G. C., Li, L., Liu, R. Y., Rehman, M., and Lee, W. M. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2036-2040
3. Simon, M. M., Reikerstorfer, A., Schwarz, A., Krone, C., Luger, T. A., Jäättelä, M., and Schwarz, T. (1995) J. Clin. Invest. 95, 926-933
4. Bellmann, K., Jäättelä, M., Wissing, D., Burkart, V., and Kolb, H. (1996) FEBS Lett. 391, 185-188
5. Bukau, B., and Horwich, A. L. (1998) Cell 92, 351-366
6. Bercovich, B., Stancovski, I., Mayer, A., Blumenfeld, N., Laszlo, A., Schwartz, A. L., and Ciechanover, A. (1997) J. Biol. Chem. 272, 9002-9010
7. Nollen, E. A., Brunsting, J. F., Roelofsen, H., Weber, L. A., and Kampinga, H. H. (1999) Mol. Cell. Biol. 19, 2069-2079
8. Buzzard, K. A., Giaccia, A. J., Killender, M., and Anderson, R. L. (1998) J. Biol. Chem. 273, 17147-17153
9. Jäättelä, M., Wissing, D., Kokholm, K., Kallunki, T., and Egeblad, M. (1998) EMBO J. 17, 6124-6134
10. Gabai, V. L., Meriin, A. B., Mosser, D. D., Caron, A. W., Rits, S., Shifrin, V. I., and Sherman, M. Y. (1997) J. Biol. Chem. 272, 18033-18037
11. Mosser, D. D., Caron, A. W., Bourget, L., Denis-Larose, C., and Massie, B. (1997) Mol. Cell. Biol. 17, 5317-5327
12. Widmann, C., Gibson, S., Jarpe, M. B., and Johnson, G. L. (1999) Physiol. Rev. 79, 143-180
13. Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R., Landvatter, S. W., Stricker, J. E., McLaughlin, M. M., Siemens, I. R., Fisher, S. M., Livi, G. P., White, J. R., Adams, J. L., and Toung, P. R. (1994) Nature 372, 739-746
14. Han, J., Lee, J. D., Bibbs, L., and Ulevitch, R. J. (1994) Science 265, 808-811
15. Beyaert, R., Cuenda, A., Vanden Berghe, W., Plaisance, S., Lee, J. C., Haegeman, G., Cohen, P., and Fiers, W. (1996) EMBO J. 15, 1914-1923
16. Lu, H. T., Yang, D. D., Wysk, M., Gatti, E., Mellman, I., Davis, R. J., and Flavell, R. A. (1999) EMBO J. 18, 1845-1857
17. Rincon, M., Enslen, H., Raingeaud, J., Recht, M., Zapton, T., Su, M. S., Penix, L. A., Davis, R. J., and Flavell, R. A. (1998) EMBO J. 17, 2817-2829
18. Wysk, M., Yang, D. D., Lu, H. T., Flavell, R. A., and Davis, R. J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3763-3768
19. Winzen, R., Kracht, M., Ritter, B., Wilhelm, A., Chen, C. Y., Shyu, A. B., Muller, M., Gaestel, M., Resch, K., and Holtmann, H. (1999) EMBO J. 18, 4969-4980
20. Kotlyarov, A., Neininger, A., Schubert, C., Eckert, R., Birchmeier, C., Volk, H. D., and Gaestel, M. (1999) Nat. Cell Biol. 1, 94-97
21. Goh, K. C., Haque, S. J., and Williams, B. R. (1999) EMBO J. 18, 5601-5608
22. Faure, V., Hecquet, C., Courtois, Y., and Goureau, O. (1999) J. Biol. Chem. 274, 4794-4800
23. Da Silva, J., Pierrat, B., Mary, J. L., and Lesslauer, W. (1997) J. Biol. Chem. 272, 28373-28380
24. Carter, A. B., Knudtson, K. L., Monick, M. M., and Hunninghake, G. W. (1999) J. Biol. Chem. 274, 30858-30863
25. Vanden Berghe, W., Plaisance, S., Boone, E., De Bosscher, K., Schmitz, M. L., Fiers, W., and Haegeman, G. (1998) J. Biol. Chem. 273, 3285-3290
26. Ensor, J. E., Wiener, S. M., McCrea, K. A., Viscardi, R. M., Crawford, E. K., and Hasday, J. D. (1994) Am. J. Physiol. 266, C967-974
27. Kluger, M. J., Rudolph, K., Soszynski, D., Conn, C. A., Leon, L. R., Kozak, W., Wallen, E. S., and Moseley, P. L. (1997) Am. J. Physiol. 273, R858-863
28. Hall, T. J. (1994) Experientia (Basel) 50, 1048-1053
29. Feinstein, D. L., Galea, E., Aquino, D. A., Li, G. C., Xu, H., and Reis, D. J. (1996) J. Biol. Chem. 271, 17724-17732
30. Wong, H. R., Finder, J. D., Wasserloos, K., and Pitt, B. R. (1995) Am. J. Physiol. 269, L843-848
31. de Vera, M. E., Kim, Y. M., Wong, H. R., Wang, Q., Billiar, T. R., and Geller, D. A. (1996) Hepatology 24, 1238-1245
32. Bernard, C., Merval, R., Esposito, B., and Tedgui, A. (1994) Eur. J. Pharmacol. 270, 115-118
33. Fincato, G., Polentarutti, N., Sica, A., Mantovani, A., and Colotta, F. (1991) Blood 77, 579-586
34. Helqvist, S., Polla, B. S., Johannesen, J., and Nerup, J. (1991) Diabetologia 34, 150-156
35. Low-Friedrich, I., Weisensee, D., Mitrou, P., and Schoeppe, W. (1992) Basic Res. Cardiol. 87, 12-18
36. Blachere, N. E., Li, Z., Chandawarkar, R. Y., Suto, R., Jaikaria, N. S., Basu, S., Udono, H., and Srivastava, P. K. (1997) J. Exp. Med. 186, 1315-1322
37. Todryk, S., Melcher, A. A., Hardwick, N., Linardakis, E., Bateman, A., Colombo, M. P., Stoppacciaro, A., and Vile, R. G. (1999) J. Immunol. 163, 1398-1408
38. Ozawa, Y., Kasuga, A., Nomaguchi, H., Maruyama, T., Kasatani, T., Shimada, A., Takei, I., Miyazaki, J., and Saruta, T. (1996) J. Autoimmun. 9, 517-524
39. Tishler, M., and Shoenfeld, Y. (1996) Semin. Arthritis Rheum. 26, 558-563
40. Landry, J., Lambert, H., Zhou, M., Lavoie, J. N., Hickey, E., Weber, L. A., and Anderson, C. W. (1992) J. Biol. Chem. 267, 794-803
41. Derijard, B., Raingeaud, J., Barrett, T., Wu, I. H., Han, J., Ulevitch, R. J., and Davis, R. J. (1995) Science 267, 682-685
42. Kyriakis, J. M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E. A., Ahmad, M. F., Avruch, J., and Woodgett, J. R. (1994) Nature 369, 156-160
43. Tanguay, R. M., Wu, Y., and Khandjian, E. W. (1993) Dev. Genet. 14, 112-118
44. Huot, J., Lambert, H., Lavoie, J. N., Guimond, A., Houle, F., and Landry, J. (1995) Eur. J. Biochem. 227, 416-427
45. Berra, E., Municio, M. M., Sanz, L., Frutos, S., Diaz-Meco, M. T., and Moscat, J. (1997) Mol. Cell. Biol. 17, 4346-4354
46. Pulverer, B. J., Kyriakis, J. M., Avruch, J., Nikolakaki, E., and Woodgett, J. R. (1991) Nature 353, 670-674
47. Darville, M. I., and Eizirik, D. L. (1998) Diabetologia 41, 1101-1108
48. Landry, J., Chretien, P., Lambert, H., Hickey, E., and Weber, L. A. (1989) J. Cell Biol. 109, 7-15
49. Kröncke, K. D., Kolb-Bachofen, V., Berschick, B., Burkart, V., and Kolb, H. (1991) Biochem. Biophys. Res. Commun. 175, 752-758
50. Lambert, H., Charette, S. J., Bernier, A. F., Guimond, A., and Landry, J. (1999) J. Biol. Chem. 274, 9378-9385
51. Lavoie, J. N., Lambert, H., Hickey, E., Weber, L. A., and Landry, J. (1995) Mol. Cell. Biol. 15, 505-516
52. Rothe, H., Burkart, V., Faust, A., and Kolb, H. (1996) Diabetologia 39, 119-122
53. Rothe, H., Faust, A., Schade, U., Kleemann, R., Bosse, G., Hibino, T., Martin, S., and Kolb, H. (1994) Diabetologia 37, 1154-1158
54. Ganiatsas, S., Kwee, L., Fujiwara, Y., Perkins, A., Ikeda, T., Labow, M. A., and Zon, L. I. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 6881-6886
55. Cuenda, A., Alonso, G., Morrice, N., Jones, M., Meier, R., Cohen, P., and Nebreda, A. R. (1996) EMBO J. 15, 4156-4164
56. Han, J., Lee, J. D., Jiang, Y., Li, Z., Feng, L., and Ulevitch, R. J. (1996) J. Biol. Chem. 271, 2886-2891
57. Morimoto, R. I. (1998) Genes Dev. 12, 3788-3796
58. Bellmann, K., Wenz, A., Radons, J., Burkart, V., Kleemann, R., and Kolb, H. (1995) J. Clin. Invest. 95, 2840-2845
59. Burston, S. G., and Clarke, A. R. (1995) Essays Biochem. 29, 125-136
60. Laroia, G., Cuesta, R., Brewer, G., and Schneider, R. J. (1999) Science 284, 499-502
61. Pilon, M., and Schekman, R. (1999) Cell 97, 679-682
62. Juo, P., Kuo, C. J., Reynolds, S. E., Konz, R. F., Raingeaud, J., Davis, R. J., Biemann, H. P., and Blenis, J. (1997) Mol. Cell. Biol. 17, 24-35
63. Meriin, A. B., Yaglom, J. A., Gabai, V. L., Zon, L., Ganiatsas, S., Mosser, D. D., and Sherman, M. Y. (1999) Mol. Cell. Biol. 19, 2547-2555
64. Dittmar, K. D., and Pratt, W. B. (1997) J. Biol. Chem. 272, 13047-13054
65. Stewart, S., Sundaram, M., Zhang, Y., Lee, J., Han, M., and Guan, K. L. (1999) Mol. Cell. Biol. 19, 5523-5534
66. Liu, H., Vuyyuru, V. B., Pham, C. D., Yang, Y., and Singh, B. (1999) Oncogene 18, 3461-3470
67. Caivano, M. (1998) FEBS Lett. 429, 249-253
68. Chan, E. D., Winston, B. W., Uh, S. T., Wynes, M. W., Rose, D. M., and Riches, D. W. (1999) J. Immunol. 162, 415-422
69. Chen, B., Chen, Y., and Lin, W. (1999) Immunology 97, 124-129
70. Guan, Z., Baier, L. D., and Morrison, A. R. (1997) J. Biol. Chem. 272, 8083-8089
71. LaPointe, M. C., and Isenovic, E. (1999) Hypertension 33, 276-282
72. Larsen, C. M., Wadt, K. A., Juhl, L. F., Andersen, H. U., Karlsen, A. E., Su, M. S., Seedorf, K., Shapiro, L., Dinarello, C. A., and Mandrup-Poulsen, T. (1998) J. Biol. Chem. 273, 15294-15300
73. Decker, T., Kovarik, P., and Meinke, A. (1997) J. Interferon Cytokine Res. 17, 121-134
74. Meraz, M. A., White, J. M., Sheehan, K. C., Bach, E. A., Rodig, S. J., Dighe, A. S., Kaplan, D. H., Riley, J. K., Greenlund, A. C., Campbell, D., Carver-Moore, K., DuBois, R. N., Clark, R., Aguet, M., and Schreiber, R. D. (1996) Cell 84, 431-442
75. Gollob, J. A., Schnipper, C. P., Murphy, E. A., Ritz, J., and Frank, D. A. (1999) J. Immunol. 162, 4472-4481
76. Guan, Z., Buckman, S. Y., Baier, L. D., and Morrison, A. R. (1998) Am. J. Physiol. 274, F673-679
77. McCartney-Francis, N., Allen, J. B., Mizel, D. E., Albina, J. E., Xie, Q. W., Nathan, C. F., and Wahl, S. M. (1993) J. Exp. Med. 178, 749-754
78. Kolb, H., and Kolb-Bachofen, V. (1998) Immunol. Today 19, 556-561

Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 International Journal of ToxicologyHome page
J. L. C. Bilszta, G. J. Dusting, and F. Jiang
Arsenite Increases Vasoconstrictor Reactivity in Rat Blood Vessels: Role of Endothelial Nitric Oxide Function
International Journal of Toxicology, July 1, 2006; 25(4): 303 - 310.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Medicherla, A. A. Protter, J. Y. Ma, R. Mangadu, R. Almirez, B. Koppelman, I. Kerr, T. A. Navas, F. Movius, M. Reddy, et al.
Preventive and Therapeutic Potential of p38{alpha}-Selective Mitogen-Activated Protein Kinase Inhibitor in Nonobese Diabetic Mice with Type 1 Diabetes
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 99 - 107.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Rafiee, Y. Shi, K. A. Pritchard Jr., H. Ogawa, A. L. W. Eis, R. A. Komorowski, C. M. Fitzpatrick, J. S. Tweddell, S. B. Litwin, K. Mussatto, et al.
Cellular Redistribution of Inducible Hsp70 Protein in the Human and Rabbit Heart in Response to the Stress of Chronic Hypoxia: ROLE OF PROTEIN KINASES
J. Biol. Chem., October 31, 2003; 278(44): 43636 - 43644.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
S. K. Roach and J. S. Schorey
Differential Regulation of the Mitogen-Activated Protein Kinases by Pathogenic and Nonpathogenic Mycobacteria
Infect. Immun., June 1, 2002; 70(6): 3040 - 3052.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
S. d. Fleming, B. W. Starnes, J. G. Kiang, A. Stojadinovic, G. C. Tsokos, and T. Shea-Donohue
Heat stress protection against mesenteric I/R-induced alterations in intestinal mucosa in rats
J Appl Physiol, June 1, 2002; 92(6): 2600 - 2607.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. LaRochelle, V. Gagne, J. Charron, J.-W. Soh, and C. Seguin
Phosphorylation Is Involved in the Activation of Metal-regulatory Transcription Factor 1 in Response to Metal Ions
J. Biol. Chem., November 2, 2001; 276(45): 41879 - 41888.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
D. S Latchman
Heat shock proteins and cardiac protection
Cardiovasc Res, September 1, 2001; 51(4): 637 - 646.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Sanada, M. Kitakaze, P. J. Papst, H. Asanuma, K. Node, S. Takashima, M. Asakura, H. Ogita, Y. Liao, Y. Sakata, et al.
Cardioprotective Effect Afforded by Transient Exposure to Phosphodiesterase III Inhibitors: The Role of Protein Kinase A and p38 Mitogen-Activated Protein Kinase
Circulation, August 7, 2001; 104(6): 705 - 710.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/24/18172    most recent
M000340200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bellmann, K.
Right arrow Articles by Landry, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bellmann, K.
Right arrow Articles by Landry, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement